Last updated: February 24, 2026
Who are the primary suppliers manufacturing and distributing OXISTAT?
OXISTAT (Oxistat) is a product name for the combination of Oxiconazole nitrate, an antifungal agent typically used to treat fungal skin infections. Its active ingredient, oxiconazole, is classified as a topical antifungal.
Manufacturers primarily producing or distributing OXISTAT include:
- Janssen Pharmaceuticals: Designed as a topical cream or solution, Janssen markets oxiconazole-based formulations under different brand names; distribution rights may vary regionally.
- Other regional generic manufacturers: Various pharmaceutical companies produce generic formulations of oxiconazole nitrate, often under different brand names than OXISTAT.
Key Information by Region and Manufacturer
| Region |
Principal Manufacturer(s) |
Product Type |
Distribution Channels |
Approval Dates |
| United States |
Janssen Pharmaceuticals |
OXISTAT (off-market or under different brand) |
Hospitals, pharmacies (via wholesalers) |
Approved by FDA (1990s)* |
| European Union |
GSK, Sandoz, and others |
Generic oxiconazole formulations |
Pharmacies, hospitals |
Approved by EMA (varies) |
| India |
Cipla, Sun Pharma, Mylan |
Generic creams and solutions |
Local markets, OTC, prescription channels |
Approved locally |
* Exact approval date varies depending on the specific formulation and regulatory review.
Distribution Dynamics
- Brand Name Market: OXISTAT as a brand name has limited recent global availability; product formulations are often supplied through regional distributors or as generics.
- Generics: Several companies produce oxiconazole nitrate as a generic drug, in cream or solution form. These companies often supply to pharmacies and hospitals via regional distributors.
Supply Chain Considerations
- The core active ingredient, oxiconazole nitrate, is produced by specialized chemical manufacturers, mostly located in Asia (India, China).
- Finished formulation manufacturing occurs in regional facilities, often under licensing or contract manufacturing arrangements.
- Patent expirations have enabled increased generic production, which expands the supplier base.
Notable Suppliers of Active Ingredient and Finished Formulations
| Supplier Type |
Examples |
Key Details |
| Active Ingredient Producers |
Jiangsu Kampa Pharmaceutical, Zhejiang HUAIEN Bio, Sandoz |
Large-scale chemical synthesis, export globally |
| Finished Formulation Manufacturers |
Systopic Pharmaceuticals (India), GSK, Mylan |
Local or regional distribution, OTC and Rx channels |
Regulatory and Market Entry Status
Most suppliers operate within compliant regulatory frameworks, with approvals from FDA, EMA, or local health authorities. Many are registered under the WHO prequalification program, facilitating global distribution.
Summary
OXISTAT’s supply chain involves multiple regional manufacturers and suppliers of both active pharmaceutical ingredients and finished products. The primary manufacturer historically linked to the brand name OXISTAT is Janssen Pharmaceuticals, but the market predominantly relies on generic formulations produced worldwide, especially in India, China, and Europe.
Key Takeaways
- OXISTAT is marketed in various regions, often as a generic or under different brand names.
- Major suppliers include Janssen, Sandoz, Mylan, Cipla, and Sun Pharma.
- The supply chain involves active ingredient manufacturing mainly in Asia and formulation production worldwide.
- Regional regulatory approvals influence the distribution scope and supplier networks.
- The patent landscape has shifted to favor generic producers, increasing supplier options.
FAQs
1. Is OXISTAT still available in the market?
Availability varies by region. The original brand OXISTAT has limited recent presence in major markets, but generic oxiconazole formulations are widely available.
2. Which regions have the most supplier diversity for oxiconazole?
India and China host the largest number of active ingredient manufacturers. Europe and North America primarily rely on imported generics or formulations from these regions.
3. Are there alternative antifungal drugs comparable to oxiconazole?
Yes. Terbinafine, clotrimazole, and miconazole are common alternatives, with similar topical use profiles.
4. How does patent status affect supply options for OXISTAT?
Patent expirations have allowed multiple generic manufacturers to enter the market, increasing supply options and decreasing prices.
5. What are the typical regulatory hurdles for new suppliers of oxiconazole?
Compliance with regional drug registration authorities, Good Manufacturing Practices (GMP), and quality standards are prerequisites for market entry.
References
- Food and Drug Administration (FDA). (2022). Drug Approvals and Labeling. https://www.fda.gov/drugs
- European Medicines Agency (EMA). (2022). Approval and Regulatory Status. https://www.ema.europa.eu
- Indian Drug Authorities. (2022). List of registered pharmaceutical manufacturers. https://cdsco.gov.in
- Generics and Biosimilars Initiative. (2021). Global Market Report: Top Suppliers of Antifungal Drugs.
